...

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >RELATIONSHIP BETWEEN ORPHAN DISEASE PREVALENCE, DIFFERENTIAL HTA VALUE ASSESSMENT, AND ORPHAN DRUG PRICING IN SEVEN EUROPEAN COUNTRIES

【24h】

RELATIONSHIP BETWEEN ORPHAN DISEASE PREVALENCE, DIFFERENTIAL HTA VALUE ASSESSMENT, AND ORPHAN DRUG PRICING IN SEVEN EUROPEAN COUNTRIES

机译：七个欧洲国家的ORPhan疾病患病率，HTA差异价值评估和ORPHAN毒品定价之间的关系

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Sladecek S.; Cockerill K.; Hegde S.; Funderburk A.; Graeve C.; Gaebler J. A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. RELATIONSHIP BETWEEN ORPHAN DISEASE PREVALENCE, DIFFERENTIAL HTA VALUE ASSESSMENT, AND ORPHAN DRUG PRICING IN SEVEN EUROPEAN COUNTRIES [J] . Sladecek S., Cockerill K., Hegde S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：七个欧洲国家的ORPhan疾病患病率，HTA差异价值评估和ORPHAN毒品定价之间的关系
2. VALUE ASSESSMENT CRITERIA FOR ORPHAN DRUGS ACROSS EIGHT EUROPEAN COUNTRIES: HTA AND BEYOND [J] . Tzouma V, Mills M., Kanavos P. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：八个欧洲国家的孤儿药物价值评估标准：HTA及以后
3. VALUE ASSESSMENT CRITERIA FOR ORPHAN DRUGS ACROSS EIGHT EUROPEAN COUNTRIES: HTA AND BEYOND [J] . Tzouma V, Mills M., Kanavos P. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：八个欧洲国家的孤儿药物价值评估标准：HTA及以后
4. GENETICALLY ENGINEERED PROBIOTIC E. COLI NISSLE TO CONSUME AMINO ACIDS ASSOCIATED WITH ORPHAN METABOLIC DISEASES [C] . Ning Li, David Lubkowicz, Vincent Isabella, Microbial engineering . 2018

机译：遗传工程化的肠埃希氏大肠杆菌（E. COLI NISSLE）食用与鸦片代谢性疾病相关的氨基酸
5. Quasi-experimental study to determine the impact of parallel trade and external reference pricing strategies utilized by the European Union (EU) on the rate of drug approval launches and patient access to U.S. designated fast track drugs and orphan drugs. [D] . King, Josephine G. 2008

机译：一项准实验研究，旨在确定欧盟（EU）使用的平行贸易和外部参考定价策略对药物批准投放率和患者使用美国指定的快速通道药物和孤儿药物的速度的影响。
6. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe [O] . Goran Medic, Daria Korchagina, Katherine Eve Young, 2017

机译：付款人重视稀有性吗？欧洲疾病罕见性与孤儿药品价格之间的关系分析
7. Relationship Between Orphan Disease Prevalence, Differential Hta Value Assessment, And Orphan Drug Pricing In Seven European Countries [O] . S Sladeček, K Cockerill, S Hegde, 2016

机译：孤儿疾病患病率，差异HTA值评估与七个欧洲国家的孤立药物定价关系

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号